Finanzen von 4D Molecular Therapeutics Inc (FDMT)FDMT4D Molecular Therapeutics Inc

Evaluating the bottom line, 4D Molecular Therapeutics Inc maintains a gross margin of 44.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2037.16%, while the net margin is -1929.01%. These profitability ratios, combined with a Return on Equity (ROE) of -43.25%, provide a clear picture of how effectively FDMT converts its operational activities into shareholder value.

In the context of the broader market, FDMT competes directly with industry leaders such as CRGX and KOD. With a market capitalization of $660.12M, it holds a significant position in the sector. When comparing efficiency, FDMT's gross margin of 44.75% stands against CRGX's N/A and KOD's N/A. Such benchmarking helps identify whether 4D Molecular Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported total revenue of 85.09 million USD in Q4 2025, a substantial increase compared to previous quarters, indicating potential growth. However, net income remains negative, with a loss of 68.76 million USD in Q1 2026.